1Bone RC,Balk RA,Cerra FB,et al.The ACCP/SCCM Consensus Conferenee Conmittee.Definitions for sepsis and organ failure and guidelines for 恤 use of innovative therapies in sepsis.Chest,1992; 101:1644-1645.
2Schetz,M,Ferdinande P,Van Den Berghe G,et al.Removal of proirflammatory cytokins with renalreplacement therapy:senes or nonsense Itensive Care Med,1995 ;21:109.
3Sander A,Armbrusteer W,Samder B,et al.Hemofiltration increases IL-6clearance in early systemicinflammatoryresponse syndrome but does not alter Ⅱ er Ⅱ IL-6and TNF-a plasconcentrations.Intensive CareMed,1997; 23:878.
4Fisher CJ J,Dhainaut JF,0pal SM,et al.Recombinanthuman interleukin-1 receptor antagonist ine treatment of patients with sepsis syndrome-results from a randomized double-blind,placebo controlledrial.JAMA,1994; 271:183-1844.
5Grootendorst AF,Van Bommel EFH,Van Der Hoven B,et al.High volume hemofiltration improves righmtricular function in endotoxin-jnduced shock in the pig.Intensive Care Med,1992; 18:235.
6Dinarello CA.Cytokines:Agents proveocateurs in hemodialysis Kidney Int,1992;41:683.
7Paseulal M,TolkoffN,Sehifferli JA,et al.Is absorption an important characteristic ofdialysismembranrs idney Int,1996;49:30.
8Rpnco GL,Brendolan AL,Dan M A,et al.Adsorption in sepsis.Kidney Int,2000 (suppl) ; 76:148-155.
9Aoki H,Kodama M,Tani T,et al.Tatment of sepsis by extracorporeal elimination of endotoxin usingolymyxin B-immobilized fiber.Am J Surg,1994; 67:412.
